Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Mark Boguniewicz to Severity of Illness Index

This is a "connection" page, showing publications Mark Boguniewicz has written about Severity of Illness Index.

 
Connection Strength
  
 
 
2.026
  
  1. Lebwohl M, Alexis AF, Beck LA, Block JK, Eichenfield LF, Fonacier L, Guttman-Yassky E, Paller AS, Pariser D, Silverberg JI, Boguniewicz M. Systemic Therapies for Moderate-to-Severe Atopic Dermatitis: Expert Perspectives in Practice J Drugs Dermatol. 2019 02 01; 18(2):122-129.
    View in: PubMed
    Score: 0.350
  2. Boguniewicz M, Sher LD, Paller AS, Arkwright PD, Yoshihara S, Chen Z, Shah P, Marco AR. Dupilumab is Efficacious in Young Children with Atopic Dermatitis Regardless of Type?2 Comorbidities. Adv Ther. 2024 Dec; 41(12):4601-4616.
    View in: PubMed
    Score: 0.130
  3. Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Tha?i D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2021 03; 9(3):1212-1223.e6.
    View in: PubMed
    Score: 0.100
  4. Boguniewicz M. Biologics for Atopic Dermatitis. Immunol Allergy Clin North Am. 2020 11; 40(4):593-607.
    View in: PubMed
    Score: 0.098
  5. Simpson E, Eckert L, Gadkari A, Mallya UG, Yang M, Nelson L, Brown M, Reaney M, Mahajan P, Guillemin I, Boguniewicz M, Pariser D. Validation of the Atopic Dermatitis Control Tool (ADCT?) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol. 2019 11 06; 19(1):15.
    View in: PubMed
    Score: 0.092
  6. Brar KK, Nicol NH, Boguniewicz M. Strategies for Successful Management of Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2019 01; 7(1):1-16.
    View in: PubMed
    Score: 0.087
  7. Silverberg JI, Chiesa Fuxench ZC, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY. Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. Ann Allergy Asthma Immunol. 2018 12; 121(6):729-734.e4.
    View in: PubMed
    Score: 0.085
  8. Silverberg JI, Gelfand JM, Margolis DJ, Fonacier L, Boguniewicz M, Schwartz LB, Simpson E, Grayson MH, Ong PY, Fuxench ZCC. Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. Ann Allergy Asthma Immunol. 2018 10; 121(4):464-468.e3.
    View in: PubMed
    Score: 0.084
  9. Fleischer AB, Boguniewicz M. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature. J Drugs Dermatol. 2010 May; 9(5):488-98.
    View in: PubMed
    Score: 0.048
  10. Nicol NH, Boguniewicz M. Successful strategies in atopic dermatitis management. Dermatol Nurs. 2008 Oct; Suppl:3-18; quiz 19.
    View in: PubMed
    Score: 0.043
  11. Boguniewicz M, Zeichner JA, Eichenfield LF, Hebert AA, Jarratt M, Lucky AW, Paller AS. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr. 2008 Jun; 152(6):854-9.
    View in: PubMed
    Score: 0.041
  12. Boguniewicz M, Abramovits W, Paller A, Whitaker-Worth DL, Prendergast M, Cheng JW, Wang P, Tong KB. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol. 2007 Apr; 6(4):416-23.
    View in: PubMed
    Score: 0.039
  13. Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, Gonzalez ME, Hebert AA, Lee M, Boguniewicz M, Simpson EL, Seal MS, Krupa D, Hanna D, Snyder S, Burnett P, Chu DH, Almaraz E, Higham RC, Berk DR. Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5?Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled Trial. Pediatr Dermatol. 2025 Mar-Apr; 42(2):296-304.
    View in: PubMed
    Score: 0.033
  14. Simpson EL, Augustin M, Tha?i D, Misery L, Armstrong AW, Blauvelt A, Papp KA, Szepietowski JC, Boguniewicz M, Kwatra SG, Kallender H, Sturm D, Ren H, Kircik L. Ruxolitinib Cream Monotherapy Improved Symptoms and Quality of Life in Adults and Adolescents with Mild-to-Moderate Atopic Dermatitis: Patient-Reported Outcomes from Two Phase III Studies. Am J Clin Dermatol. 2025 Jan; 26(1):121-137.
    View in: PubMed
    Score: 0.033
  15. Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC, Siegfried EC, Tom WL, Paller AS. Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A US Expert Consensus. Dermatology. 2024; 240(5-6):897-909.
    View in: PubMed
    Score: 0.032
  16. Kenney HM, Yoshida T, Berdyshev E, Calatroni A, Gill SR, Simpson EL, Lussier S, Boguniewicz M, Hata T, Chiesa Fuxench ZC, De Benedetto A, Ong PY, Ko J, Davidson W, David G, Schlievert PM, Leung DYM, Beck LA. CERS1 is a biomarker of Staphylococcus aureus abundance and atopic dermatitis severity. J Allergy Clin Immunol. 2025 Feb; 155(2):479-490.
    View in: PubMed
    Score: 0.032
  17. Simpson EL, Guttman-Yassky E, Eichenfield LF, Boguniewicz M, Bieber T, Schneider S, Guana A, Silverberg JI. Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibition. Allergy. 2023 11; 78(11):2875-2891.
    View in: PubMed
    Score: 0.030
  18. Simpson EL, Schlievert PM, Yoshida T, Lussier S, Boguniewicz M, Hata T, Fuxench Z, De Benedetto A, Ong PY, Ko J, Calatroni A, Rudman Spergel AK, Plaut M, Quataert SA, Kilgore SH, Peterson L, Gill AL, David G, Mosmann T, Gill SR, Leung DYM, Beck LA. Rapid reduction in Staphylococcus aureus in atopic dermatitis subjects following dupilumab treatment. J Allergy Clin Immunol. 2023 11; 152(5):1179-1195.
    View in: PubMed
    Score: 0.030
  19. Simpson EL, De Benedetto A, Boguniewicz M, Ong PY, Lussier S, Villarreal M, Schneider LC, Paller AS, Guttman-Yassky E, Hanifin JM, Spergel JM, Barnes KC, David G, Austin B, Leung DYM, Beck LA. Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry. J Allergy Clin Immunol Pract. 2023 08; 11(8):2504-2515.
    View in: PubMed
    Score: 0.029
  20. Leung DYM, Bissonnette R, Kreimer S, Berdyshev E, Bafna S, Lyubchenko T, Richers BN, Garcia S, Ramirez-Gama M, Hall CF, Xiao O, Taylor P, Boguniewicz M, Levit NA, Agueusop I, Zhang A, Goleva E. Dupilumab Inhibits Vascular Leakage of Blood Proteins Into Atopic Dermatitis Skin. J Allergy Clin Immunol Pract. 2023 05; 11(5):1421-1428.
    View in: PubMed
    Score: 0.029
  21. Simpson E, Armstrong A, Boguniewicz M, Chiesa Fuxench ZC, Feely M, Pierce E, Sun L, Chen YF, Angle R, Silverberg JI. Baricitinib 2?mg for the treatment of atopic dermatitis in North America: Long-term efficacy and patient-reported outcomes. Dermatol Ther. 2022 12; 35(12):e15954.
    View in: PubMed
    Score: 0.028
  22. Reich K, Lio PA, Bissonnette R, Alexis AF, Lebwohl MG, Pink AE, Kabashima K, Boguniewicz M, Nowicki RJ, Valdez H, Zhang F, DiBonaventura M, Cameron MC, Clibborn C. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2022 Dec; 10(12):3228-3237.e2.
    View in: PubMed
    Score: 0.028
  23. Blauvelt A, Boguniewicz M, Brunner PM, Luna PC, Biswas P, DiBonaventura M, Farooqui SA, Rojo R, Cameron MC. Abrocitinib monotherapy in Investigator's Global Assessment nonresponders: improvement in signs and symptoms of atopic dermatitis and quality of life. J Dermatolog Treat. 2022 Aug; 33(5):2605-2613.
    View in: PubMed
    Score: 0.028
  24. Wollenberg A, Beck LA, de Bruin Weller M, Simpson EL, Imafuku S, Boguniewicz M, Zachariae R, Olsen CK, Thyssen JP. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2022 03; 186(3):453-465.
    View in: PubMed
    Score: 0.027
  25. Silverberg JI, Simpson EL, Boguniewicz M, De Bruin-Weller MS, Foley P, Kataoka Y, B?go-Le-Bagousse G, Chen Z, Shumel B, Chao J, Rossi AB. Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. Acta Derm Venereol. 2021 Nov 10; 101(11):adv00585.
    View in: PubMed
    Score: 0.027
  26. Silverberg JI, Chiesa-Fuxench Z, Margolis D, Boguniewicz M, Fonacier L, Grayson M, Simpson E, Ong P. Epidemiology and Burden of Sleep Disturbances in Atopic Dermatitis in US Adults. Dermatitis. 2022 Nov-Dec 01; 33(6S):S104-S113.
    View in: PubMed
    Score: 0.025
  27. Siegfried EC, Bieber T, Simpson EL, Paller AS, Beck LA, Boguniewicz M, Schneider LC, Khokhar FA, Chen Z, Prescilla R, Mina-Osorio P, Bansal A. Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial. Am J Clin Dermatol. 2021 Mar; 22(2):243-255.
    View in: PubMed
    Score: 0.025
  28. Paller AS, Siegfried EC, Tha?i D, Wollenberg A, Cork MJ, Arkwright PD, Gooderham M, Beck LA, Boguniewicz M, Sher L, Weisman J, O'Malley JT, Patel N, Hardin M, Graham NMH, Ruddy M, Sun X, Davis JD, Kamal MA, Khokhar FA, Weinreich DM, Yancopoulos GD, Beazley B, Bansal A, Shumel B. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11?years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020 Nov; 83(5):1282-1293.
    View in: PubMed
    Score: 0.024
  29. Paller AS, Bansal A, Simpson EL, Boguniewicz M, Blauvelt A, Siegfried EC, Guttman-Yassky E, Hultsch T, Chen Z, Mina-Osorio P, Lu Y, Rossi AB, He X, Kamal M, Graham NMH, Pirozzi G, Ruddy M, Eckert L, Gadkari A. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. Am J Clin Dermatol. 2020 Feb; 21(1):119-131.
    View in: PubMed
    Score: 0.023
  30. Simpson EL, Paller AS, Siegfried EC, Boguniewicz M, Sher L, Gooderham MJ, Beck LA, Guttman-Yassky E, Pariser D, Blauvelt A, Weisman J, Lockshin B, Hultsch T, Zhang Q, Kamal MA, Davis JD, Akinlade B, Staudinger H, Hamilton JD, Graham NMH, Pirozzi G, Gadkari A, Eckert L, Stahl N, Yancopoulos GD, Ruddy M, Bansal A. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2020 01 01; 156(1):44-56.
    View in: PubMed
    Score: 0.023
  31. Silverberg JI, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Fuxench ZC, Simpson EL. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol. 2020 01; 182(1):104-111.
    View in: PubMed
    Score: 0.023
  32. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL. Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults. J Invest Dermatol. 2019 10; 139(10):2090-2097.e3.
    View in: PubMed
    Score: 0.022
  33. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL. Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. Br J Dermatol. 2019 09; 181(3):554-565.
    View in: PubMed
    Score: 0.022
  34. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench Z, Simpson EL. Atopic Dermatitis in US Adults: From Population to Health Care Utilization. J Allergy Clin Immunol Pract. 2019 May - Jun; 7(5):1524-1532.e2.
    View in: PubMed
    Score: 0.022
  35. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Chiesa Fuxench ZC, Simpson EL. Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults. J Invest Dermatol. 2019 06; 139(6):1388-1391.
    View in: PubMed
    Score: 0.022
  36. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Ong PY, Fuxench ZC, Simpson EL. Health Utility Scores of Atopic Dermatitis in US Adults. J Allergy Clin Immunol Pract. 2019 04; 7(4):1246-1252.e1.
    View in: PubMed
    Score: 0.022
  37. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, Tofte S, Dunn JD, Feldman SR, Clark AR, Schwartz G, Eichenfield LF. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. Am J Clin Dermatol. 2018 Dec; 19(6):821-838.
    View in: PubMed
    Score: 0.022
  38. Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, Grayson MH, Margolis DJ, Mitchell L, Silverberg JI, Schwartz L, Simpson EL, Ong PY. Atopic Dermatitis in America Study: A?Cross-Sectional Study Examining the Prevalence?and Disease Burden of Atopic Dermatitis in the US Adult Population. J Invest Dermatol. 2019 03; 139(3):583-590.
    View in: PubMed
    Score: 0.021
  39. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. Ann Allergy Asthma Immunol. 2018 11; 121(5):604-612.e3.
    View in: PubMed
    Score: 0.021
  40. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, Simpson EL, Ong PY, Chiesa Fuxench ZC. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018 09; 121(3):340-347.
    View in: PubMed
    Score: 0.021
  41. Simpson EL, Villarreal M, Jepson B, Rafaels N, David G, Hanifin J, Taylor P, Boguniewicz M, Yoshida T, De Benedetto A, Barnes KC, Leung DYM, Beck LA. Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype. J Invest Dermatol. 2018 10; 138(10):2224-2233.
    View in: PubMed
    Score: 0.021
  42. Schneider L, Hanifin J, Boguniewicz M, Eichenfield LF, Spergel JM, Dakovic R, Paller AS. Study of the Atopic March: Development of Atopic Comorbidities. Pediatr Dermatol. 2016 Jul; 33(4):388-98.
    View in: PubMed
    Score: 0.018
  43. Hata TR, Audish D, Kotol P, Coda A, Kabigting F, Miller J, Alexandrescu D, Boguniewicz M, Taylor P, Aertker L, Kesler K, Hanifin JM, Leung DY, Gallo RL. A randomized controlled double-blind investigation of the effects of vitamin D dietary supplementation in subjects with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014 Jun; 28(6):781-9.
    View in: PubMed
    Score: 0.015
  44. Grigoryev DN, Howell MD, Watkins TN, Chen YC, Cheadle C, Boguniewicz M, Barnes KC, Leung DY. Vaccinia virus-specific molecular signature in atopic dermatitis skin. J Allergy Clin Immunol. 2010 Jan; 125(1):153-159.e28.
    View in: PubMed
    Score: 0.012
  45. Langley RG, Eichenfield LF, Lucky AW, Boguniewicz M, Barbier N, Cherill R. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis. Pediatr Dermatol. 2008 May-Jun; 25(3):301-7.
    View in: PubMed
    Score: 0.010
  46. Abramovits W, Hebert AA, Boguniewicz M, Kempers SE, Tschen E, Jarratt MT, Lucky AW, Cornelison RL, Swinyer LJ, Jones TM. Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults. J Dermatolog Treat. 2008; 19(6):327-32.
    View in: PubMed
    Score: 0.010
  47. Spergel JM, Boguniewicz M, Paller AS, Hebert AA, Gallagher PR, McCormick C, Parneix-Spake A, Hultsch T. Addition of topical pimecrolimus to once-daily mid-potent steroid confers no short-term therapeutic benefit in the treatment of severe atopic dermatitis; a randomized controlled trial. Br J Dermatol. 2007 Aug; 157(2):378-81.
    View in: PubMed
    Score: 0.010
  48. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006 Mar; 5(3):236-44.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)